The oral loading test with tetrahydrobiopterin (BH 4 ) is used to discriminate between variants of hyperphenylalaninaemia and to detect BH 4 -responsive patients. The outcome of the loading test depends on the genotype, dosage of BH 4 , and BH 4 pharmacokinetics. A total of 71 patients with hyperphenylalaninaemia (mild to classic) were challenged with BH 4 (20 mg/kg) according to different protocols (1 × 20 mg or 2 × 20 mg) and blood BH 4 concentrations were measured in dried blood spots at different time points (T 0 , T 2 , T 4 , T 8 , T 12 , T 24 , T 32 and T 48 h ). Maximal BH 4 concentrations (median 22.69 nmol/g Hb) were measured 4 h after BH 4 administration in 63 out of 71 patients. Eight patients presented with maximal BH 4 concentrations ∼44% higher at 8 h than at 4 h. After 24 h, BH 4 blood concentrations dropped to 11% of maximal values. This profile was similar using different protocols. The following pharmacokinetic parameters were calculated for BH 4 in blood: t max = 4 h, AUC (T 0−32 ) = 370 nmol × h/g Hb, and t 1/2
for absorption (1.1 h), distribution (2.5 h), and elimination (46.0 h) phases. Maximal BH 4 blood concentrations were not significantly lower in non-responders and there was no correlation between blood concentrations and responsiveness. Of mild PKU patients, 97% responded to BH 4 administration, while one was found to be a non-responder. Only 10/19 patients (53%) with Phe concentrations of 600-1200 μmol/L responded to BH 4 administration, and of the patients with the severe classical phenotype (blood Phe > 1200 μmol/L) only 4 out of 17 patient responded. An additional 36 patients with mild hyperphenylalaninaemia (HPA) who underwent the combined loading test with Phe+BH 4 were all responders. Slow responders and non-responders were found in all groups of HPA.
Introduction
The loading test with tetrahydrobiopterin (BH 4 ) is an essential and integral part of the differential diagnosis for hyperphenylalaninaemia (HPA) (Blau et al 2001) . This test discriminates between BH 4 responders and non-responders and is particularly important for detection of patients with BH 4 -responsive phenylalanine hydroxylase (PAH; EC 1.14.16.1) deficiency (Blau and Erlandsen 2004) . In BH 4 responders, blood phenylalanine (Phe) declines 4-24 h after BH 4 administration (20 mg/kg body weight), with almost complete Fig. 1 Definition of the BH 4 responsiveness after oral administration of BH 4 (20 mg/kg). RR: rapid responder; MR: moderate responder; SR: slow responder; NR: non-responder; ND not defined normalization after 4-8 h in patients with BH 4 deficiency. BH 4 -responsive PAH patients were initially defined as showing a decrease of blood Phe concentrations of 30% after 8 h and 30-50% after 24 h (Bernegger and Blau 2002) and most of them belong to the group of mild HPA and mild and moderate phenylketonuria (PKU; OMIM 262600) (Desviat et al 2004; Fiori et al 2005; Kure et al 1999; Lässker et al 2002; Lindner et al 2003; Lücke et al 2003; Matalon et al 2004; Mitchell et al 2005; Muntau et al 2002; Perez-Duenas et al 2004; Spaapen et al 2001; Steinfeld et al 2003; Trefz and Blau 2003) . Sensitivity of the test was further improved by multiple administrations of BH 4 and by longer observation time Shintaku et al 2004) . Efficiency and interpretation of the loading test depends on several factors such as amount of administered BH 4 , severity of HPA, dietary management, and genotype. The pharmacokinetics of BH 4 was suggested as an additional factor affecting the loading test; however, this was never investigated in patients with PKU (Fiege et al 2004) .
The aim of this study was to estimate basic kinetic parameters for BH 4 in blood after administration of BH 4 and following the combined Phe+BH 4 loading test, and to correlate the BH 4 concentrations in blood with the outcome of the test.
Materials and methods

Patients
A total of 71 HPA patients in whom BH 4 deficiency had been excluded were loaded with a single dose of BH 4 (20 mg/kg); 35 of them presented with basal blood Phe concentrations <600 μmol/L, 19 with Phe concentrations of 600-1200 μmol/L, and 17 with Phe concentrations >1200 μmol/L. In 11 patients with blood Phe concentrations of 278-1575 μmol/L the standard test was extended by the administration of another 20 mg/kg BH 4 after 24 h. An additional 36 patients with basal Phe concentrations of 384-739 μmol/L underwent a combined Phe (100 mg/kg) and BH 4 (20 mg/kg) loading test.
Mutation analysis was done in only a few patients and was not included in this study. The study was performed after a formal consensus of patients or their parents and in accordance with the Helsinki recommendations 1989.
Loading test
The single BH 4 test, the extended test, and the combined Phe+BH 4 loading test were performed as described previously using the 6R-BH 4 (Schircks Laboratories, Jona, Switzerland) (Blau and Erlandsen 2004; Fiege et al 2005) . In patients loaded with a single dose of BH 4 (20 mg/kg), blood was collected at times T 0 , T 4 , T 8 and T 24 h . In 45 of them additional blood collections were done at T 2 , T 12 and T 48 h . In patients loaded with 2 × 20 mg/kg BH 4 , blood was collected at T 0 , T 4 , T 8 , T 24 , T 32 and T 48 h , and in patients loaded with Phe+BH 4 the following blood collections were performed: T −3 (Phe administration), T 0 (BH 4 administration), T 4 , T 8 and T 24 h .
The following criteria were used to define BH 4 -responsiveness over 24 h : 'rapid responder', reduction of blood Phe by ≥30% at T 8 , and ≥50% at T 24 ; 'moderate responder', reduction of blood Phe by ≥20% at T 8 , and ≥30% at T 24 ; 'slow responder', reduction of blood Phe by <20% at T 8 , and ≥20% at T 24 ( Fig. 1) . BH 4 and Phe in blood BH 4 was measured in dried blood spots according to the method of Zurflüh and colleagues (2005) and calculated as the sum of total biopterin and pterin (nmol BH 4 /g Hb). The following protocol was used: For each measurement, four blood circles (Ø6 mm) were cut out and pterins were extracted with 250 μL of 20 mmol/L HCl and placed in an ultrasonic bath for 30 s. Pterins were extracted by mixing the filter 25th-75th percentiles; ⊥ 5th percentile; T 95th percentile; + min/max spot solution for 10 min at room temperature. The extract was centrifuged at 1800 × g for 5 min at room temperature. Clear supernatatant (60 μL) was used for analysis of haemoglobin on the haematology analyser Sysmex KX-21N (Sysmex Corporation, Japan). The remaining supernatant was ultrafiltered on Ultrafree (NMWL 10000; Millipore) at 5000 × g for 15 min. Pterins were analysed in clear filtrate by HPLC and fluorescence detection without prior oxidation (Zurflüh et al 2005) .
Phe was measured using standard ion-exchange chromatography of amino acids or tandem-mass spectrometry.
Statistical analyses
WinSTAT for Excel (v. 2003 .1) was used for descriptive statistics and for regression analysis. Pharmacokinetic parameters were calculated using the PK Solutions software, v. 2.0 (Summit Research Services, Montrose, CO).
Results
BH 4 kinetics in blood
In 63 out of 71 patients with HPA loaded with 20 mg/kg BH 4 , blood BH 4 concentrations reached highest values after 4 h (median = 22.65 nmol/g Hb; 5th-95th percentiles = 10.07-49.97 nmol/g Hb). Four hours later (T 8 ) BH 4 concentrations decreased by 42% (median = 13.61 nmol/g Hb; 5th-95th percentiles = 5.25-31.63 nmol/g Hb) and after 24 h BH 4 concentrations were only 11% of maximal values (median = 2.29 nmol/g Hb; 5th-95th percentiles = 0.67-5.35 nmol/g Hb). In 8 out of 71 patients, blood BH 4 concentrations were ∼44 % higher at 8 h than values at 4 h after administration and the highest single BH 4 value was 96.39 nmol/g Hb at T 4 h .
In 45 of the above patients the blood BH 4 profile was investigated over 32 h after BH 4 administration (20 mg/kg) with additional time points at T 2 , T 12 and T 32 h (Fig. 2) . Two hours after BH 4 administration (median = 16.30 nmol/g Hb; 5th-95th percentiles = 6.84-28.44 nmol/g Hb) blood concentrations reached about 70% of the maximal concentrations found after 4 h. At 12 h (median = 6.15 nmol/g Hb; 5th-95th percentiles = 2.90-12.38 nmol/g Hb) and 32 h (median = 2.03 nmol/g Hb; 5th-95th percentiles = 0.51-5.47 nmol/g Hb) BH 4 blood concentrations were lower than those at 8 h (47% and 15%, respectively).
In 11 patients the protocol was extended to a second administration of BH 4 (20 mg/kg) after 24 h (Fig. 3) . Blood was collected 8 (T 32 ) and 24 (T 48 ) hours after the second administration and compared with T 8 concentrations for BH 4 in blood (median = 15.37 nmol/g Hb; 5th-95th percentiles = 7.05-54.02 nmol/g Hb); T 32 values were 17% lower (median = 12.80 nmol/g Hb; 5th-95th percentiles = 7.41-38.54 nmol/g Hb). There was no significant difference in BH 4 concentrations at T 24 and T 48 h .
Thirty-six patients with blood Phe concentrations of <336 μmol/L were loaded first with Phe (100 mg/kg) and three hours later with BH 4 (20 mg/kg), and blood samples were collected before Phe administration (T −3 ), before BH 4 administration (i.e. 3 h after Phe loading; T 0 ), and 4, 8 and 24 h after BH 4 administration (T 4−24 ) (Fig. 4) . BH 4 concentrations in blood increased in 26/36 patients after Phe administration by 111% (BH 4 at T −3 , median = 0.30 nmol/g Hb; 5th-95th percentiles = 0.12-2.77 nmol/g Hb; BH 4 at T 0 , median = 0.52 nmol/g Hb; 5th-95th percentiles = 0.16-4.43 nmol/g Hb). The following profile of BH 4 kinetics was similar as the one described for a single BH 4 administration, with maximal blood concentrations at T 4 (median = 22.01 nmol/g Hb; 5th-95th percentiles = 10.40-46.58 nmol/g Hb), 25% lower concentrations at T 8 (median = 16.46 nmol/g Hb; 5th-95th percentiles = 4.66-33.49 nmol/g Hb), and 90% lower concentrations at T 24 (median = 2.09 nmol/g Hb; 5th-95th percentiles = 0.55-6.84 nmol/g Hb). In 6 subjects maximal BH 4 concentrations were reached after 8 h. Based on data obtained over 32 h after a single BH 4 administration (20 mg/kg) in 45 patients with HPA, basic pharmacokinetic parameters were calculated: t max was 4 h, AUC (T 0−32 ) was 370 nmol × h/g Hb, and t 1/2 for absorption, distribution, and elimination phases was 1.1, 2.5, and 46.0 h, respectively.
Responsiveness to BH 4 Table 1 summarizes the results of the loading test with 20 mg/kg BH 4 in patients with HPA. Responsiveness was calculated according to criteria defined in Fig. 1 . 34/35 patients (97%) with basal blood Phe concentrations <600 μmol/L responded to BH 4 administration, one patient was found to be a non-responder. Only 10/19 patients (53%) with basal blood Phe concentrations of 600-1200 μmol/L responded to BH 4 administration, and of the patients with the severe classical phenotype (blood Phe > 1200 μmol/L) only four patients responded (24%), and two of them were slow responders (Fig. 5) . The lower the Phe at T 0 the higher the probability that a patient will respond to BH 4 . Two patients could not be assigned to the above-mentioned criteria; one would have been positioned somewhere between moderate and slow responder and the other was at the level of a All 36 patients who underwent the combined loading test with Phe+BH 4 were classified as responders (data not shown).
In order to demonstrate whether absorption of BH 4 may affect the outcome of the loading test, maximal blood BH 4 concentrations were compared with responsiveness to BH 4 , but no correlation was found (Fig. 6 ). Highest maximal blood BH 4 concentrations were found in two rapid responders.
Discussion
Extensive pharmacokinetic studies of BH 4 have been performed in animal models (Hayashi et al 1992) , but only a few parameters are known from studies in humans (Fiege and Blau 2006) . Some pharmacokinetic parameters are known from oral administration of BH 4 tablets to healthy adult human volunteers and might provide details on pharmacological response to BH 4 therapy (Fiege et al 2004) . Plasma concentrations of BH 4 and total biopterin were assessed after oral administration of 6R-BH 4 at different doses to different healthy subjects and preliminary pharmacokinetic parameters have been determined (Fiege et al 2004) . The plasma profile of total biopterin after oral administration exhibited first-order kinetics, showing a fast absorption phase (T 0 -T 4 ), a rapid decline (T 4 -T 10 ) corresponding to the absorption and distribution phase, followed by a slower decline in the final elimination phase (T 10 -T 33 h ). Total biopterin concentrations in plasma have been studied after administration of different doses (10 and 20 mg/kg) to one healthy adult subject (Fiege et al 2004) . Maximal plasma concentrations in this subject were reached 4 h after the 10 mg/kg dose and 3 h after the 20 mg/kg dose, at concentrations of 258.7 and 441.7 nmol/L, respectively. The AUC 0−10 after administration of 20 mg/kg was 1.6 times higher than the AUC after the 10 mg/kg dosage (3046 vs 1958 nmol h/L). Based on these data, the elimination kinetics seem to be only slightly faster at higher plasma concentrations (t max = 4.2 h vs 5.1 h) (Fiege et al 2004) .
Very little is known about BH 4 pharmacokinetics in patients with HPA. Shintaku and colleagues (2005) reported plasma biopterin concentrations in two patients with HPA who underwent a single BH 4 loading test (10 mg/kg) at different ages. In both patients plasma biopterin concentrations were ∼100% higher at an early age (<1 month) compared with concentratiuons measured at the age of 2 months. Also, biopterin concentrations peaked at 4 h at the age of 1 month, compared with maximal concentrations at 2 h at the age of 2 months. The authors suggested that BH 4 responsiveness in the same individual or the same genotype may correlate with biopterin concentration, but in different genotypes this might not be the case (Shintaku et al 2005) .
We were not able to see any statistical difference between different age groups in our patients (data not shown). Similarly to what was described for healthy controls (Fiege et al 2004) , blood BH 4 peaked at 4 h in 90% of patients with HPA. This profile was consistent regardless of whether patients were loaded with one or two BH 4 doses or after Phe administration (Figs. 2-4) . Two hours after BH 4 administration, blood concentrations were about 70% of the maximal BH 4 concentrations, indicating a very fast absorption phase (t 1/2 = 1.1 h). In our patients, oral administration of BH 4 resulted in a fast distribution phase (t 1/2 = 2.5 h), followed by a slow elimination phase (t 1/2 = 46.0 h). Thus, although a single BH 4 administration may be sufficient for the interpretation of the loading test, additional dosages can potentate the effect and increase the sensitivity Shintaku et al 2004) .
Data from the combined Phe+BH 4 loading test show that administration of Phe (100 mg/kg) almost doubled blood BH 4 concentrations after 3 h in 72% of patients (Fig. 4) . This is consistent with previous findings that biopterin concentrations in urine or plasma correlate with blood phenylalanine concentrations (Dhondt and Farriaux, 1982; Ponzone et al 1993) but have no consequences on the outcome of the loading test. Phenylalanine administration does not influence BH 4 concentrations upon oral BH 4 administration. As expected, all patients in this group were classified as responders and one should question how useful this test is. Factors such as spontaneous Phe elimination (Desviat et al 2004) or daily fluctuations (Leuzzi et al 2006) may influence the interpretation, and from our experience the combined loading test is not recommended. It can be only used in patients who are already on a strict low-phenylalanine diet with normalized blood phenylalanine concentrations.
One of the main goals of this study was to evaluate the effect of blood BH 4 concentrations on the outcome of the loading tests. Recently we described a single case with HPA (BH 4 -responsive genotype) showing intra-individual variations in BH 4 absorption on two occasions, which resulted in different BH 4 blood concentrations and influenced the responsiveness (Zurflüh et al 2005) . We were not able to repeat the loading test in non-responders in this study, but maximal BH 4 blood concentrations were not significantly lower in this group of patients. Indeed, maximal BH 4 blood concentrations were only 3% lower in non-responders than in all responders, and slow responders had 7% and 42% higher concentrations than moderate or rapid responders, respectively (data not shown).
With regard to the responsiveness to BH 4 , our data confirm previous observations that rapid responders belong mainly to the groups of mild HPA and mild PKU, and that patients with classical PKU show either only a slow response or none at all (Fig. 5) . Nevertheless, slow responders and non-responders were found in all groups of HPA.
